Pharmicell (005690) Q2 2026 earnings summary

Executive summary

• Operates two main divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (pharmaceutical intermediates, specialty chemicals).

• Listed on KOSPI since 1988, with no subsidiaries or affiliates as of the reporting date.

• Significant R&D focus, with multiple clinical trials and government-supported projects in progress.

Financial highlights

• Revenue for H1 2026: KRW 75.7 billion, down from KRW 114.1 billion in H1 2025.

• Operating income: KRW 26.3 billion (H1 2026), down from KRW 34.3 billion (H1 2025).

• Net income: KRW 22.1 billion (H1 2026), down from KRW 40.3 billion (H1 2025).

• Basic EPS: KRW 368 (H1 2026) vs. KRW 671 (H1 2025).

• Cash and equivalents at period end: KRW 15.0 billion, down from KRW 28.9 billion at prior year-end.

Outlook and guidance

• Continued investment in R&D, especially for stem cell therapies and pharmaceutical intermediates.

• Ongoing construction of Ulsan Plant 3 to expand production capacity for AI materials and pharmaceutical ingredients.

• Plans to balance shareholder returns with growth investments; no changes to dividend policy.